ID
22015
Beschrijving
Study part: Protocol exceptions. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"
Trefwoorden
Versies (1)
- 14-05-17 14-05-17 -
Houder van rechten
Roche
Geüploaded op
14 mei 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
PROTOCOL EXCEPTIONS Roche H0650g Breast Cancer
PROTOCOL EXCEPTIONS
- StudyEvent: ODM
Beschrijving
2. IF YES. PLEASE INDICATE THE NUMBER(S) OF ELIGIBILITY CRITERIA FROM THE WORKSHEET WHICH WERE NOT SATISFIED AND PROVIDE A BRIEF DESCRIPTION OF EACH. PL.EASE ALSO SPECIFY THE NAME OF THE EMPLOYEE CONTACTED FOR APPROVAL AND THE DATE APPROVAL WAS OBTAINED
Beschrijving
Eligibility Criteria
Datatype
text
Alias
- UMLS CUI [1]
- C1516637
Beschrijving
description Eligibility Criteria
Datatype
text
Alias
- UMLS CUI [1,1]
- C0678257
- UMLS CUI [1,2]
- C1516637
Beschrijving
investigator name
Datatype
text
Alias
- UMLS CUI [1]
- C2826892
Beschrijving
DATE OF CONTACT
Datatype
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0332158
Beschrijving
Investigator name
Datatype
text
Alias
- UMLS CUI [1]
- C2826892
Similar models
PROTOCOL EXCEPTIONS
- StudyEvent: ODM
C0545082 (UMLS CUI [1,2])
C1516637 (UMLS CUI [1,2])
C0332158 (UMLS CUI [1,2])